Compare Charles River Laboratories Intl. Inc (CRL) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Garmin Ltd. — how do they compare? Charles River Laboratories Intl. Inc trades at $229.26 (market cap $11.14B), while Garmin Ltd. trades at $245.03 (market cap $46.55B). The key difference: Garmin Ltd. is far larger — about 4.2× Charles River Laboratories Intl. Inc's market cap, and Garmin Ltd. pays a 1.74% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | GRMN | |
|---|---|---|
Market Cap | $11.14B | $46.55B |
Sector | Health | Technology |
52-Week High | $233.60 | $267.52 |
52-Week Low | $145.57 | $187.10 |
Enterprise Value | $14.00B | $44.02B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Garmin (GRMN) trades at $243.61, up 0.21% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth, reaching $7.25B in 2025, with a net income margin of 23.26%. Recent product launches, including AXIS flight displays and LiveScope 2 sonar, highlight innovation. The stock is near its pivot point of $243, with support at $242 and resistance at $245.
Outlook remains positive with a consensus price target of $282.67, implying 16% upside. Risks include competitive pressures in consumer electronics and aviation markets. Analyst sentiment is mixed, with 74% hold ratings, but earnings beats in recent quarters support growth trajectory. Dividend payments provide shareholder returns, with the next payment scheduled for September 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
